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Key Points
Question
What are contemporary trends in the characteristics and outcomes of patients with newly diagnosed
cirrhosis?
Findings
In this cohort study of 9261 patients with newly diagnosed cirrhosis from 2004 to 2014, the proportions of
patients younger than 40 years and those 65 years and older increased significantly, as did the proportions
with alcoholic cirrhosis and nonalcoholic steatohepatitis. Mortality decreased over time.
Meaning
The population of patients with newly diagnosed cirrhosis is facing changes in demographic characteristics,
clinical features, and outcomes that may affect future care.
Abstract
Importance
Changes in the characteristics of patients with cirrhosis are likely to affect future outcomes and are
important to understand in planning for the care of this population.
Objective
To identify changes in demographic and clinical characteristics and outcomes in patients with newly
diagnosed cirrhosis.
Design, Setting, and Participants
A retrospective cohort study of patients with a new diagnosis of cirrhosis was conducted using the Indiana
Network for Patient Care, a large statewide regional health information exchange, between 2004 and 2014.
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Patients with at least 1 year of continuous follow-up before the cirrhosis diagnosis were followed up through
August 1, 2015. The analysis was conducted from December 2018 to January 2019.
Exposures
Age, cause of cirrhosis, and year of diagnosis.
Main Outcomes and Measures
Overall rates for mortality, liver transplant, hepatocellular carcinoma, and hepatic decompensation
(composite of ascites, hepatic encephalopathy, or variceal bleeding).
Results
A total of 9261 patients with newly diagnosed cirrhosis were identified (mean [SD] age, 57.9 [12.6] years;
5109 [55.2%] male). A 69% increase in new diagnoses occurred over the course of the study period (620 in
2004 vs 1045 in 2014). The proportion of those younger than 40 years increased by 0.20% per year (95%
CI, 0.04% to 0.36%; P for trend = .02), and the proportion of those aged 65 years and older increased by
0.81% per year (95% CI, 0.51% to 1.11%; P for trend < .001). The proportion of patients with alcoholic
cirrhosis increased by 0.80% per year (95% CI, 0.49% to 1.12%), and the proportion with nonalcoholic
steatohepatitis increased by 0.59% per year (95% CI, 0.30% to 0.87%), whereas the proportion with viral
hepatitis decreased by 1.36% per year (95% CI, −1.68% to −1.03%) (P < .001 for all). In patients younger
than 40 years, 40 to 64 years, and 65 years and older, mortality rates were 6.4 (95% CI, 5.4 to 7.6), 9.9 (95%
CI, 9.5 to 10.4), and 16.2 (95% CI, 15.2 to 17.2) per 100 person-years, respectively (P < .001). Mortality
rates decreased during the study period (11.9 [95% CI, 10.7-13.1] per 100 person-years in 2004 vs 10.0
[95% CI, 8.1-12.2] per 100 person-years in 2014; annual adjusted hazard ratio, 0.87 [95% CI, 0.86 to 0.88])
and were lower in those with alcoholic cirrhosis compared with patients with viral hepatitis (adjusted hazard
ratio, 0.89 [95% CI, 0.80 to 0.98]). Rates of hepatocellular carcinoma were low in patients younger than 40
years (0.5 [95% CI, 0.2 to 0.9] per 100 person-years). Liver transplant rates were low throughout the study
period (0.3 [95% CI, 0.3-0.4] per 100 person-years). In patients with compensated cirrhosis, rates of hepatic
decompensation were lower in patients younger than 40 years (adjusted subhazard ratio 0.78; 95% CI, 0.62
to 0.99) and in patients with nonalcoholic steatohepatitis (adjusted subhazard ratio, 0.51; 95% CI, 0.43 to
0.60).
Conclusions and Relevance
The population of patients with newly diagnosed cirrhosis in Indiana has experienced changes in the age
distribution and cause of cirrhosis, with decreasing mortality rates. These findings support investment in the
prevention and treatment of alcoholic liver disease and nonalcoholic steatohepatitis, particularly in younger
and older patients. Additional study is needed to identify the reasons for decreasing mortality rates.
Introduction
Cirrhosis is the end point of a variety of chronic liver diseases and can lead to such complications as ascites,
variceal bleeding, and hepatic encephalopathy. These complications contribute to cirrhosis being the 12th
leading cause of death in the United States.  Cirrhosis is also the primary risk factor for hepatocellular
carcinoma (HCC), which is increasing in incidence and associated mortality.
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These outcomes are influenced by patient demographic and clinical characteristics. For example, increases
in cirrhosis-related mortality in young adults have been ascribed to alcohol use.  In contrast, cirrhosis due to
nonalcoholic steatohepatitis (NASH) is more commonly diagnosed in older patients, who have lower rates
of transplant and greater mortality while waiting for a transplant.  Viral hepatitis, which in the United States
is most prevalent among baby boomers, is strongly associated with HCC.  As these characteristics change
on a population level, we would expect to see corresponding changes in outcomes. Recent data show
increases in alcohol use disorders in the general population as well as an increase in alcoholic cirrhosis–
related mortality.  The epidemics of obesity and diabetes have resulted in increasing frequency of NASH,
with corresponding increases in transplant referrals.  With respect to viral hepatitis, the expanding
availability of effective antiviral agents may lead to improved outcomes.  In contrast to these recent
changes in the United States, much of our knowledge of the natural history of cirrhosis is derived from older
studies and studies performed elsewhere.
Understanding changes in the demographic characteristics, clinical characteristics, and outcomes of patients
with cirrhosis is therefore critical to allocating resources and prioritizing future research. An improved
understanding of the contemporary natural history of cirrhosis can also better inform medical decision
making. To explore these trends, we used data from the Indiana Network for Patient Care, a statewide
repository of clinical and administrative data from a variety of sources. We hypothesized that we would be
able to identify trends in patient characteristics with implications for outcomes.
Methods
Study Design
This study was approved by the Indiana University institutional review board. Informed consent was waived
because this study used deidentified retrospective data. This report follows the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) reporting guideline.  We performed a retrospective
cohort study of patients with newly diagnosed cirrhosis between 2004 and 2014 in the Indiana Network for
Patient Care, the largest interorganizational clinical data repository in the United States, connecting more
than 46 000 clinicians, 16 000 practices, and 110 hospitals across Indiana. It contains inpatient and
outpatient data from more than 14 million patients, including both administrative and clinical data, as well
as death certificate information for patients who die inside and outside Indiana.  Claims-based definitions
based on International Classification of Diseases, Ninth Revision, Clinical Modification or Current
Procedural Terminology codes are provided in eTable 1 in the Supplement. Patients were included if they
(1) were aged 18 years or older at the time of diagnosis and (2) had at least 2 separate claims for cirrhosis,
according to previously validated codes.  To ensure that these were incident cirrhosis diagnoses (ie, new
diagnoses), we required at least 1 year of continuous follow-up in the Indiana Network for Patient Care
before the first cirrhosis claim. We excluded patients with a claim for any solid-organ transplant during this
1-year period.
Patients were followed up in the cohort from the time of the initial cirrhosis claim until the first of the
following events: (1) death, (2) liver transplant, or (3) administrative censoring on August 1, 2015. This date
was chosen to avoid irregularities due to the transition to International Classification of Diseases, Tenth
Revision. The 1-year run-in period was not counted as person-time in the cohort. The analysis was
conducted from December 2018 to January 2019.
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Variables
The primary variables of interest were age at the time of diagnosis and cause of cirrhosis. Outcomes
included mortality, liver transplant, HCC, and hepatic decompensation. Incidence estimates of HCC and
decompensation excluded patients with these complications in the first 180 days of follow-up, because these
are likely to be prevalent complications.
The cause of cirrhosis was defined on the basis of the presence of diagnostic codes and laboratory results
during either the run-in period or follow-up time (eTable 1 in the Supplement). For those with viral hepatitis
and another cause (eg, alcohol), the cause was considered to be viral hepatitis. Patients with alcohol and
another nonviral cause were considered to have alcohol-induced cirrhosis. Where available, validated
coding algorithms were used.  Patients without 1 of the listed diagnoses were considered to have NASH
or another cause of liver disease.
Comorbidities were assessed only during the run-in period and were determined according to the Deyo
modification of the Charlson comorbidity index.  The liver disease categories were excluded to avoid
double counting the cirrhosis complications.  Ascites during follow-up was defined by the presence of a
code for ascites or paracentesis or by the presence of ascites laboratory specimen. The presence of hepatic
encephalopathy, variceal bleeding, and HCC during follow-up was determined on the basis of diagnostic
codes. Decompensation was defined by the occurrence of ascites, hepatic encephalopathy, or variceal
bleeding during follow-up. These complications of liver disease were considered to be prevalent (ie, present
at cirrhosis diagnosis) when they were identified in the first 180 days of follow-up.
Statistical Analysis
Categorical variables were described using counts and percentages, and bivariable comparisons were
performed with Pearson χ  test. Continuous variables were described using means and standard deviations,
and comparisons were made using 1-way analysis of variance. Temporal linear trends in proportions were
assessed using the Cochran-Armitage test for trend. We used survival analysis to examine differences in
outcomes based on age and cause of cirrhosis and to examine temporal trends in outcomes. Mortality
outcomes were compared using the log-rank test and Cox proportional hazards regression, and other
outcomes were compared using competing risk regression, accounting for the competing risk of death that
would prevent the outcome of interest (eg, death prevents a patient from undergoing liver transplant).
Multivariable models included age, sex, cause of cirrhosis, decompensation at baseline, Charlson
comorbidity index, health insurance, and year of cirrhosis diagnosis. Two-sided tests were used, and P < .05
was considered statistically significant. Analyses were performed using Stata statistical software version 13
(StataCorp).
Sensitivity Analyses
We repeated analyses of trends and outcomes for causes of cirrhosis after restricting the NASH definition.
This definition of NASH was based on the presence of a NASH diagnostic code or the presence of
metabolic syndrome without an alternative cause of cirrhosis. Metabolic syndrome was defined according to
guidelines established by the National Cholesterol Education Program Adult Treatment Panel III,
according to the presence of at least 3 of the following factors: obesity, dyslipidemia, hypertension, and
impaired fasting glucose or diabetes, with corresponding diagnostic codes.
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Results
Patient Characteristics
The cohort included 9261 patients with cirrhosis, of whom 585 (6.3%) were younger than 40 years, 6027
(65.1%) were aged 40 to 64 years, and 2649 (28.6%) were aged 65 years and older. The mean (SD) age was
57.9 (12.6) years; 5109 patients (55.2%) were men. The median (interquartile range) duration of follow-up
was 2.1 (0.7-4.5) years. Overall patient characteristics and comparisons between the age groups are shown
in Table 1. The younger and older groups had higher proportions of women compared with those aged 40 to
64 years (285 [48.7%] and 1366 [51.6%] vs 2501 [41.5%]). The leading causes of cirrhosis were alcohol in
the group younger than 40 years, viral hepatitis in the group aged 40 to 64 years, and NASH in the group
aged 65 years and older. At baseline, 3149 patients (34.0%) had decompensation, and of those, 2111
(67.0%) had ascites and 1613 (51.2%) had hepatic encephalopathy (similar across age groups).
Hepatocellular carcinoma was present in 439 patients (4.7%) and was more common among older patients
(174 [6.6%] of those aged ≥65 years vs 6 [1.0%] of those aged <40 years). Older patients also had a greater
burden of comorbidities; 1425 (53.8%) of those aged 65 years and older had at least 2 comorbidities
(excluding their liver disease) compared with 2156 (35.8%) of those aged 40 to 64 years and 148 (25.3%) of
those younger than 40 years. The top payers were Medicaid for those younger than 40 years (199 patients
[36.7%]), commercial insurance for those aged 40 to 64 years (1664 patients [31.0%]), and Medicare for
those aged 65 years and older (2226 patients [89.8%]).
Comparisons of the different causes of cirrhosis are shown in Table 2. The group with viral hepatitis had the
highest proportion of men (2237 [62.0%]), and the group with autoimmune or cholestatic disease had the
highest proportion of women (141 [58.7%]). Patients with alcoholic cirrhosis and NASH had higher
proportions of baseline decompensation (1247 [40.2%] and 893 [38.7%], respectively) than did patients
with viral hepatitis (945 [26.2%]). At baseline, HCC was present in 265 (7.3%) of those with viral hepatitis,
compared with only 70 (2.3%) of those with alcoholic cirrhosis and 92 (4.0%) of those with NASH. The
comorbidity burden was greatest among those with NASH.
Trends in Baseline Characteristics
Between 2004 and 2014, new diagnoses of cirrhosis increased by 69% (620 in 2004 vs 1045 in 2014). The
proportion of those younger than 40 years increased by 0.20% per year (95% CI, 0.04% to 0.36%; P for
trend = .02), whereas the proportion of those aged 65 years and older increased by 0.81% per year (95% CI,
0.51% to 1.11%; P for trend < .001) (Figure, A). The mean (SD) age increased from 56.0 (13.1) years in
2004 to 59.1 (13.1) years in 2014. Annual changes in baseline characteristics are shown in Table 3. The sex
distribution did not change over time, but the cause of liver disease did change. The proportion of liver
cirrhosis due to alcohol increased by 0.80% (95% CI, 0.49% to 1.12%) and the proportion due to NASH
increased by 0.59% per year (95% CI, 0.30% to 0.87%), whereas the proportion due to viral hepatitis
decreased by 1.36% per year (95% CI, −1.68% to −1.03%) (P < .001 for all) (Figure, B). The increase in
alcohol-related cirrhosis was seen in all age groups and was most pronounced in patients younger than 40
years (2.32% per year; 95% CI, 1.02% to 3.62%) (Table 3). There was an increase in baseline
decompensation by 1.80% per year (95% CI, 1.49% to 2.12%) across age groups, with greater increases for
ascites (1.84% per year; 95% CI, 1.56% to 2.12%) compared with hepatic encephalopathy (0.85% per year;
95% CI, 0.59% to 1.10%). Comorbidity burden also increased over time, particularly in those aged 40 to 64
years and in those aged 65 years and older, with the proportion of patients with 4 or more comorbidities
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Mortality
Transplant
Hepatocellular Carcinoma
Decompensation
increasing by 0.39% per year (95% CI, 0.08% to 0.70%) and 0.75% per year (95% CI, 0.20% to 1.30%),
respectively. The prevalence of HCC did not change over time.
Outcomes
During follow-up, 3026 patients (32.7%) died: 126 (21.5%) of those younger than 40 years, 1924
(31.9%) of those aged 40 to 64 years, and 976 (36.8%) of those aged 65 years and older. Corresponding
mortality rates were 6.4 (95% CI, 5.4-7.6), 9.9 (95% CI, 9.5-10.4), and 16.2 (95% CI, 15.2-17.2) per 100
person-years, respectively (P < .001) (eTable 2 in the Supplement). The higher mortality rate in those aged
65 years and older was attenuated after multivariable adjustment (hazard ratio [HR], 1.10; 95% CI, 0.98-
1.23). These differences in mortality associated with age were present in patients with both compensated
and decompensated cirrhosis, although the differences were more apparent in patients with compensated
cirrhosis (eFigure 1 in the Supplement). Corresponding 1-, 2-, and 5-year cumulative survival rates are
shown in eTable 3 in the Supplement. Mortality rates decreased during the study period (11.9 [95% CI,
10.7-13.1] per 100 person-years in 2004 vs 10.0 [95% CI, 8.1-12.2] per 100 person-years in 2014; annual
adjusted HR, 0.87; 95% CI, 0.86-0.88) (Table 4). Compared with cirrhosis due to viral hepatitis, alcoholic
cirrhosis was associated with reduced mortality (adjusted HR, 0.89; 95% CI, 0.80-0.98), and NASH was
associated with increased overall mortality (adjusted HR, 1.44; 95% CI, 1.30-1.60) in both bivariable and
multivariable analyses (eTable 4 in the Supplement). The reduced mortality associated with alcohol was
more apparent for those with decompensated cirrhosis; the increased mortality associated with NASH was
more apparent for those with compensated cirrhosis (eFigure 2 in the Supplement). This reduction in
mortality was present across age groups and different cirrhosis causes and persisted after multivariable
adjustment.
Liver transplant was performed for 88 patients (1.0%), at similar rates across age groups (eTable
2 in the Supplement). Transplant rates were low (0.3 [95% CI, 0.3-0.4] per 100 person-years) and decreased
during the study period (annual adjusted subhazard ratio [SHR], 0.88; 95% CI, 0.81-0.94) (Table 4).
Transplant rates were lower in patients with NASH (adjusted SHR, 0.32; 95% CI, 0.12-0.82) than in
patients with viral hepatitis (eTable 4 in the Supplement).
The incidence of HCC was low in patients younger than 40 years, with an
absolute incidence rate of 0.5 (95% CI, 0.2-0.9) per 100 person-years; 7 (88%) of these patients who
developed HCC had viral hepatitis (eTable 2 in the Supplement). Older patients had a similar absolute risk
of HCC compared with those aged 40 to 64 years, but after multivariable adjustment, the risk was increased
(SHR, 1.58; 95% CI, 1.13-2.22). This increased risk appeared to be associated with the cause of cirrhosis. In
those without viral hepatitis, the adjusted SHR for older patients was 1.24 (95% CI, 0.79-1.95); in those
with viral hepatitis, the adjusted SHR was 1.82 (95% CI, 1.19-2.78). The rate of HCC in those aged 40 to 64
years with viral hepatitis was 2.7 (95% CI, 2.3-3.0) per 100 person-years, and in those aged 65 years and
older it was 4.4 (95% CI, 3.2-5.9) per 100 person-years compared with all patients without viral hepatitis
(0.9 [95% CI, 0.8-1.1] per 100 person-years). The rate of incident HCC remained constant (Table 4).
Patients younger than 40 years with compensated cirrhosis had a lower rate of subsequent
decompensation compared with older patients (adjusted SHR, 0.78; 95% CI, 0.62-0.99), predominantly
associated with a lower rate of hepatic encephalopathy (adjusted SHR, 0.53; 95% CI, 0.36-0.78) (eTable 2
in the Supplement). Nonalcoholic steatohepatitis was associated with lower rates of incident ascites
(adjusted SHR, 0.46; 95% CI, 0.37-0.56), hepatic encephalopathy (adjusted SHR, 0.38; 95% CI, 0.28-0.50),
variceal bleeding (adjusted SHR, 0.28; 95% CI, 0.16-0.47), and overall decompensation (adjusted SHR,
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0.51; 95% CI, 0.43-0.60) (eTable 4 in the Supplement). Rates of decompensation increased over the study
period, largely because of an increase in the incidence of ascites (Table 4). Rates of hepatic encephalopathy
and variceal bleeding did not change over time.
Sensitivity Analyses
Restricting the definition of NASH led to an increase in NASH prevalence (0.38% per year; 95% CI,
0.21%-0.55%; P < .001) but also to an increased prevalence among those aged 65 years and older (0.48%
per year; 95% CI, 0.05%-0.91%; P = .03) as opposed to the nonsignificant decrease shown in Table 3. The
excess mortality associated with NASH in the primary analysis (eTable 4 in the Supplement) was largely
associated with patients without a recorded cause of cirrhosis; those with the restricted NASH definition had
unadjusted mortality rates similar to those for the other causes (10.5 [95% CI, 9.1-12.1] per 100 person-
years) and reduced mortality after multivariable adjustment (HR, 0.82; 95% CI, 0.69-0.97). Other outcomes
were unaffected by the alternative NASH definition.
Discussion
In this statewide cohort study of patients with newly diagnosed cirrhosis over a decade, we found increases
in the proportion of those younger than 40 years and 65 years and older, as well as increases in the
proportions of patients with alcoholic cirrhosis and NASH, with a decrease in the proportion of patients with
viral hepatitis. The increasing burden of alcoholic liver disease in younger adults is consistent with the
findings of several other studies. One study of US death certificates  showed an increase in cirrhosis-related
mortality in young adults from 2009 to 2016 driven by alcoholic liver disease. Another study  of
commercially insured adults in the United States showed an increase in the prevalence of alcoholic cirrhosis,
with this increase most pronounced in younger patients. Hospitalization costs for cirrhosis have also
increased in recent years because of an increasing burden of alcoholic cirrhosis.  More broadly, in a
nationally representative sample, high-risk drinking and alcohol use disorders increased from 2001 to 2013
across all age groups, with the highest absolute risk among younger adults.  Future projections based on
epidemiologic data also support an increasing effect of alcohol on the population with cirrhosis.  Our study
provides data showing that these increases in alcohol use, cirrhosis prevalence, mortality, and costs are also
reflected in an increasing number of new diagnoses of alcoholic cirrhosis in younger adults. The long-term
costs of this shift include lost productivity in those of prime working age, as well as costs associated with
liver disease surveillance (eg, HCC and varices) in younger patients with longer life expectancies.
These data support the allocation of resources to reduce the burden of alcohol use disorder, which is
increasingly leading to advanced liver disease.
In addition to the increasing numbers of younger patients with alcoholic cirrhosis, we also found increased
numbers of older patients and those with NASH-related cirrhosis. These findings reflect the obesity
epidemic and are consistent with studies showing an increasing prevalence of NASH and increasing
numbers of older patients and those with NASH-related cirrhosis pursuing liver transplant.
Importantly, these shifts have implications for the future because patients with new diagnoses now may
require transplant years later. Other studies have projected such increases in NASH- and obesity-related
transplants decades after increases in obesity prevalence.  These trends may also negatively affect the
population of patients who need transplant because their increasing comorbidity burden will render them
less suitable for transplant.  Notably, we found an increasing comorbidity burden in this study, particularly
in older patients.
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In contrast to these increases, there was a relative decrease in the number of patients aged 40 to 64 years
with newly diagnosed cirrhosis and in the number of cases of cirrhosis due to viral hepatitis. These trends
likely reflect the aging of the cohort of patients with hepatitis C (most of whom were born 1945-1965),
whose ages ranged from 39 in 2004 to 69 in 2014. It is important to note that the absolute numbers of those
aged 40 to 64 years and those with viral hepatitis did increase until 2011; however, these increases were
smaller than those in the comparator groups, resulting in a relative decrease. However, from 2011 onward,
the absolute numbers of these patients decreased by 13%. These decreases cannot be attributed to highly
effective treatment regimens for hepatitis C, which were not available until 2013; rather, these figures likely
reflect the fact that the incidence of new hepatitis C infections has been decreasing since the 1980s.  With
the current widespread treatment of hepatitis C, we would anticipate more drastic reductions of viral
hepatitis–related cirrhosis and its complications in the future.
A significant finding was the decreasing mortality rate, which has been seen in other studies.  One
study  posited a shift of inpatient mortality to the immediate postdischarge setting, but nevertheless found
reduced 1-year mortality. Although this study does not allow us to definitively comment on reasons for this
improvement, it may be associated with improved care. For hospitalized patients with cirrhosis, timely
endoscopy and paracentesis have been linked to decreasing mortality.  Others have found increasing use
of antibiotics, an intervention with proven mortality benefit, for patients with cirrhosis and upper
gastrointestinal tract bleeding.  The mortality improvement in our study occurred despite an increasing
prevalence of decompensation both at diagnosis and during follow-up (mostly ascites). The reason for this
increase in baseline decompensation is unclear, but it may reflect the shift in causes of cirrhosis away from
viral hepatitis and toward alcohol and NASH. Notably, baseline decompensation was much more common
among patients with alcoholic and NASH cirrhosis compared with patients with viral hepatitis. Patients with
viral hepatitis may be more likely to undergo liver fibrosis assessment at an asymptomatic phase, whereas in
patients with alcoholism and NASH, liver disease may be diagnosed only after symptoms of end-stage liver
disease occur. The decrease in mortality also occurred despite extremely low rates of transplant, which also
decreased during the study period. This low transplant rate highlights the importance of focusing on quality
care to improve outcomes, because transplant alone is unlikely to achieve these goals on a population scale.
Future work should continue to explore reasons for these mortality trends.
The prevalence of baseline HCC and incident HCC during follow-up remained stable over time. This
finding is in contrast to those of other studies  showing an increase in HCC incidence, driven primarily
by hepatitis C. However, these studies analyzed patients treated in the Veterans Affairs system, who have a
greater prevalence of viral hepatitis; therefore, those results may not be generalizable to the general
population. In contrast, our study includes patients from multiple health systems and payers, and our
findings may be more generalizable. One study  of Surveillance, Epidemiology, and End Results Program
data did show decreasing HCC incidence and mortality rates in particular racial and ethnic groups in recent
years. Another notable finding is the extremely low prevalence (1%) and incidence (0.5 per 100 person-
years) of HCC in younger patients, which has been seen elsewhere.  If confirmed, these data could support
less stringent HCC surveillance in the growing population of younger patients with cirrhosis.
Limitations
There are several limitations to this study. Although the Indiana Network for Patient Care covers multiple
health systems, it is not a true population-based cohort and does not have complete coverage of Indiana.
However, it is the nation’s oldest, largest, and most comprehensive regional health information exchange,
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and its inclusion of multiple payers including Medicare and Medicaid makes it a unique data source to
follow a large, diverse population longitudinally. This is in contrast to other studies that are limited to single
payers or health systems.  In addition, although Indiana has relatively high rates of alcohol use disorders
and alcoholic cirrhosis–associated mortality, the state is not an outlier compared with other states, which
further enhances the generalizability of the findings. We used diagnostic and procedural codes to identify
cirrhosis and other factors that can be associated with misclassification errors. However, when possible, we
used codes that had been previously validated. Furthermore, limiting the cohort to only incident cirrhosis
diagnoses (with a 1-year run-in period) does not represent the entire population with cirrhosis. Indeed, the
observed low transplant rate likely reflects that most patients with cirrhosis receive a diagnosis shortly after
entering the health care system. However, specifying the cohort in this way allows for the identification of
incident diagnoses more accurately than including all cirrhosis diagnoses, and it provides a more robust way
to assess outcomes. Notably, the mortality estimates in this study are similar to those of prior natural history
studies of cirrhosis.  Other strengths of the study include the large sample size, broad geographic
representation throughout Indiana, and linkage to the Social Security death index, which supports accurate
mortality estimates.
Conclusions
This study found a shifting profile of the population of those with newly diagnosed cirrhosis that is likely to
affect clinical care and future outcomes. These data can help inform contemporary natural history
projections for different causes of cirrhosis in different age groups. Of particular interest are the increased
number of diagnoses in younger and older patients and increases in the numbers of cases of alcoholic
cirrhosis and NASH. We also found changes in outcomes, notably a decreasing mortality rate. Together,
these data support the allocation of resources toward the prevention of alcoholic liver disease and the
treatment of NASH, as well as understanding ways to better care for these increasing populations. In
addition, existing models of care that have focused on populations of predominantly viral hepatitis–induced
cirrhosis have been useful; however, new models to better address the unique needs of younger and older
patients with cirrhosis (eg, dedicated care focusing on treatment of alcohol use disorders and comorbidities
associated with NASH) are needed to continue to improve outcomes.
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Figures and Tables
Table 1.
Baseline Characteristics
Characteristic Patients, No. (%) P Value
All Ages <40 y 40-64 y ≥65 y
Total 9261 585 (6.3) 6027 (65.1) 2649 (28.6)
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Male 5109 (55.2) 300 (51.3) 3526 (58.5) 1283 (48.4) <.001
Cause of cirrhosis
Alcohol 3103 (33.5) 270 (46.2) 1976 (32.8) 857 (32.4)
<.001
Viral 3610 (39.0) 167 (28.5) 2995 (49.7) 448 (16.9)
Nonalcoholic steatohepatitis or other 2308 (24.9) 128 (21.9) 940 (15.6) 1240 (46.8)
Autoimmune or cholestatic 240 (2.6) 20 (3.4) 116 (1.9) 104 (3.9)
Decompensated 3149 (34.0) 219 (37.4) 2018 (33.5) 912 (34.4) .13
Ascites 2111 (67.0) 147 (67.1) 1362 (67.5) 602 (66.0) .73
Hepatic encephalopathy 1613 (51.2) 117 (53.4) 1039 (51.5) 457 (50.1) .63
Hepatocellular carcinoma 439 (4.7) 6 (1.0) 259 (4.3) 174 (6.6) <.001
Charlson comorbidity index
0 3711 (40.1) 322 (55.0) 2656 (44.1) 733 (27.7)
<.001
1 1821 (19.7) 115 (19.7) 1215 (20.2) 491 (18.5)
2-3 1939 (20.9) 81 (13.8) 1152 (19.1) 706 (26.7)
≥4 1790 (19.3) 67 (11.5) 1004 (16.7) 719 (27.1)
Insurance
Commercial 1954 (23.3) 149 (27.5) 1664 (31.0) 141 (5.7)
<.001
Medicare 3566 (42.6) 71 (13.1) 1269 (23.7) 2226 (89.8)
Medicaid 1745 (20.8) 199 (36.7) 1488 (27.8) 58 (2.3)
Other 1115 (13.3) 123 (22.7) 939 (17.5) 53 (2.1)
Percentage of patients with decompensated cirrhosis.
Table 2.
Baseline Characteristics According to Cause of Cirrhosis
Characteristic Patients, No. (%) P
ValueAlcohol
(n = 3103)
Viral
(n = 3610)
NASH or Other
(n = 2308)
Autoimmune or Cholestatic
(n = 240)
Age, mean (SD), y 56.7 (12.4) 54.6 (9.3) 64.5 (14.4) 60.8 (13.9) <.001
Male 1666 (53.7) 2237 (62.0) 1107 (48.0) 99 (41.3) <.001
Decompensated 1247 (40.2) 945 (26.2) 893 (38.7) 64 (26.7) <.001
Ascites 839 (67.3) 723 (76.5) 508 (56.9) 41 (64.1) <.001
Hepatic
encephalopathy
684 (54.9) 383 (4.5) 514 (57.6) 32 (50.0) <.001
a
a
a
a
a
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Hepatocellular
carcinoma
70 (2.3) 265 (7.3) 92 (4.0) 12 (5.0) <.001
Charlson
comorbidity index
0 1325 (42.7) 1672 (46.3) 598 (25.9) 116 (48.3)
<.001
1 671 (21.6) 705 (19.5) 407 (17.6) 38 (15.8)
2-3 636 (20.5) 705 (19.5) 554 (24.0) 44 (18.3)
≥4 471 (15.2) 528 (14.6) 749 (32.5) 42 (17.5)
Insurance
Commercial 722 (26.4) 757 (22.8) 407 (19.2) 68 (33.0)
<.001
Medicare 1118 (40.9) 1011 (3.4) 1330 (62.9) 107 (51.9)
Medicaid 489 (17.9) 1044 (31.4) 202 (9.6) 10 (4.9)
Other 403 (14.8) 515 (15.5) 176 (8.3) 21 (10.2)
Abbreviation: NASH, nonalcoholic steatohepatitis.
Percentage of patients with decompensated cirrhosis.
Figure.
Temporal Trends in Ages of Patients at Diagnosis and in Causes of Cirrhosis
Temporal trends in ages of patients at diagnosis (A) and in causes of cirrhosis (B). NASH indicates nonalcoholic
steatohepatitis.
Table 3.
Temporal Trends in Patient Characteristics
Characteristic All Ages <40 y 40-64 y ≥65 y
Change per
Year, %
P
Value
Change per
Year, %
P
Value
Change per
Year, %
P
Value
Change
per Year,
P
Value
a
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(95% CI) (95% CI) (95% CI) % (95%
CI)
Male −0.11 (−0.44
to 0.23)
.53 0.06 (−1.24 to
1.36)
.92 −0.08 (−0.49
to 0.32)
.69 0.14
(−0.48 to
0.76)
.66
Cause of
cirrhosis
Alcohol 0.80 (0.49 to
1.12)
<.001 2.32 (1.02 to
3.62)
<.001 0.70 (0.31 to
1.09)
<.001 0.63 (0.04
to 1.21)
.03
Viral −1.36 (−1.68
to −1.03)
<.001 −2.88 (−4.06
to −1.70)
<.001 −1.30 (−1.72
to −0.89)
<.001 −0.07
(−0.53 to
0.39)
.77
Nonalcoholic
steatohepatitis or
other
0.59 (0.30 to
0.87)
<.001 0.71 (−0.37 to
1.79)
.20 0.58 (0.28 to
0.88)
<.001 −0.35
(−0.97 to
0.27)
.27
Autoimmune or
cholestatic
−0.03 (−0.14
to 0.07)
.55 −0.15 (−0.62
to 0.33)
.54 0.03 (−0.09
to 0.14)
.66 −0.20
(−0.44 to
0.04)
.10
Baseline
decompensation
1.80 (1.49 to
2.12)
<.001 2.16 (0.90 to
3.42)
<.001 1.75 (1.36 to
2.14)
<.001 1.81 (1.22
to 2.40)
<.001
Ascites 1.84 (1.56 to
2.12)
<.001 1.94 (0.81 to
3.07)
<.001 1.91 (1.56 to
2.25)
<.001 1.67 (1.15
to 2.19)
<.001
Hepatic
encephalopathy
0.85 (0.59 to
1.10)
<.001 1.12 (0.08 to
2.16)
.04 0.70 (0.39 to
1.02)
<.001 1.10 (0.63
to 1.57)
<.001
Hepatocellular
carcinoma
0.13 (−0.01 to
0.28)
.06 −0.09 (−0.35
to 0.17)
.50 0.16 (−0.01
to 0.32)
.07 0.10
(−0.21 to
0.40)
.55
Charlson
comorbidity
 
 
 
 
 
  
 
 
   
  
      
 
   
 
   
 
Table 4.
Temporal Trends in Clinical Outcomes
Outcome by Cause of
Cirrhosis
Incidence Rate (95% CI) per 100 Person-
Years
HR or SHR (95% CI)
2004-2006 2007-2011 2012-2014 Crude Adjusted
Mortality 11.7 (11.0-
12.4)
11.0 (10.5-
11.6)
9.9 (9.0-10.8) 0.90 (0.89-
0.91)
0.87 (0.86-
0.88)
Alcohol 10.3 (9.2- 9.2 (8.4-10.1) 8.2 (7.0-9.6) 0.89 (0.87- 0.86 (0.84-
a
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11.5) 0.91) 0.88)
Viral 9.4 (8.5-10.4) 9.8 (9.0-10.6) 9.0 (7.7-10.5) 0.93 (0.91-
0.95)
0.90 (0.88-
0.92)
NASH or other 22.1 (19.7-
24.8)
18.2 (16.6-
19.9)
15.2 (12.9-
17.8)
0.87 (0.85-
0.88)
0.84 (0.82-
0.86)
Autoimmune or cholestatic 12.3 (8.6-
17.7)
8.7 (6.1-12.4) 6.3 (3.1-12.5) 0.84 (0.77-
0.91)
0.84 (0.76-
0.92)
Transplant 0.3 (0.2-0.5) 0.3 (0.2-0.4) 0.3 (0.2-0.5) 0.90 (0.84-
0.97)
0.88 (0.81-
0.94)
Alcohol 0.3 (0.1-0.6) 0.4 (0.3-0.7) 0.3 (0.1-0.7) 0.93 (0.84-
1.03)
0.92 (0.83-
1.03)
Viral 0.4 (0.2-0.6) 0.2 (0.2-0.4) 0.3 (0.2-0.8) 0.89 (0.79-
1.01)
0.86 (0.76-
0.98)
NASH or other 0.2 (0.0-0.6) 0.2 (0.1-0.4) 0.0 (0.0-0.0) 0.81 (0.65-
1.01)
NA
Autoimmune or cholestatic 0.8 (0.2-3.3) 1.4 (0.6-3.5) 0.8 (0.1-5.6) 0.92 (0.76-
1.12)
1.04 (0.74-
1.46)
Hepatocellular carcinoma 1.6 (1.4-1.9) 1.8 (1.6-2.1) 1.8 (1.4-2.3) 1.01 (0.97-
1.04)
1.01 (0.98-
1.05)
Alcohol 1.1 (0.7-1.6) 0.9 (0.6-1.2) 1.0 (0.6-1.8) 0.96 (0.88-
1.04)
0.96 (0.87-
1.05)
Viral 2.3 (1.9-2.9) 2.9 (2.5-3.4) 3.1 (2.3-4.3) 1.03 (0.99-
1.08)
1.03 (0.99-
1.07)
NASH or other 0.6 (0.3-1.3) 0.8 (0.5-1.3) 0.8 (0.3-1.8) 0.99 (0.88-
1.12)
0.97 (0.85-
1.10)
Autoimmune or cholestatic 0.5 (0.1-3.3) 2.8 (1.4-5.6) 2.3 (0.6-9.1) 1.11 (0.92-
1.33)
1.11 (0.76-
1.62)
Decompensation 7.7 (7.0-8.4) 10.8 (10.1-
11.5)
15.0 (13.5-
16.7)
1.04 (1.02-
1.06)
1.04 (1.02-
1.06)
Alcohol 7.1 (6.0-8.4) 11.2 (9.9-
12.6)
17.3 (14.7-
20.4)
1.06 (1.03-
1.09)
1.06 (1.02-
1.09)
Viral 9.3 (8.2-10.4) 12.2 (11.2-
13.4)
15.2 (12.9-
17.9)
1.02 (1.00-
1.05)
1.02 (1.00-
1.05)
NASH or other 4.0 (3.0-5.5) 6.6 (5.4-8.0) 11.7 (9.0-
15.1)
1.06 (1.01-
1.11)
1.06 (1.01-
1.12)
Autoimmune or cholestatic 7.6 (4.5-12.8) 9.5 (6.3-14.3) 10.8 (5.4-
21.7)
1.04 (0.93-
1.15)
1.05 (0.94-
1.18)
Ascites 5.6 (5.0-6.2) 8.3 (7.8-9.0) 11.7 (10.4-
13.1)
1.07 (1.05-
1.09)
1.07 (1.05-
1.09)
Alcohol 4.8 (3.9-5.8) 7.8 (6.8-8.9) 13.2 (11.0-
16.0)
1.10 (1.06-
1.14)
1.10 (1.06-
1.14)
b
c
c
Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604080/?report=printable[9/3/2019 11:30:08 AM]
Viral 6.9 (6.1-7.9) 9.9 (9.0-10.9) 12.4 (10.3-
14.8)
1.06 (1.03-
1.08)
1.06 (1.03-
1.08)
NASH or other 3.2 (2.3-4.6) 5.1 (4.1-6.4) 8.0 (5.9-10.9) 1.06 (1.00-
1.12)
1.07 (1.00-
1.13)
Autoimmune or cholestatic 4.6 (2.4-8.8) 8.0 (5.2-12.4) 9.5 (4.5-19.9) 1.13 (1.01-
1.28)
1.12 (0.98-
1.27)
Hepatic encephalopathy 3.6 (3.1-4.0) 4.7 (4.2-5.1) 5.4 (4.5-6.4) 1.02 (1.00-
1.05)
1.02 (0.99-
1.05)
Alcohol 3.3 (2.6-4.2) 5.7 (4.8-6.6) 6.8 (5.3-8.8) 1.06 (1.02-
1.10)
1.04 (1.00-
1.09)
Viral 4.3 (3.6-5.0) 5.1 (4.5-5.8) 5.3 (4.0-7.0) 1.01 (0.97-
1.04)
1.01 (0.97-
1.05)
NASH or other 1.6 (1.0-2.6) 1.8 (1.3-2.7) 3.4 (2.1-5.5) 1.01 (0.93-
1.09)
0.99 (0.90-
1.09)
Autoimmune or cholestatic 4.4 (2.3-8.4) 3.4 (1.8-6.6) 2.6 (0.7-10.5) 0.94 (0.80-
1.10)
0.97 (0.82-
1.15)
Variceal bleeding 1.6 (1.3-1.9) 1.9 (1.7-2.3) 2.3 (1.8-3.0) 0.99 (0.95-
1.02)
1.00 (0.96-
1.04)
Alcohol 1.4 (1.0-2.0) 2.7 (2.1-3.4) 2.4 (1.6-3.8) 1.02 (0.96-
1.08)
1.00 (0.94-
1.07)
Viral 2.1 (1.6-2.6) 2.1 (1.7-2.6) 2.9 (2.0-4.2) 0.96 (0.91-
1.01)
0.97 (0.92-
1.03)
NASH or other 0.2 (0.0-0.8) 0.5 (0.3-1.0) 1.4 (0.7-2.9) 1.14 (0.96-
1.36)
1.20 (0.97-
1.47)
Autoimmune or cholestatic 1.5 (0.5-4.7) 0.4 (0.1-2.6) 0.0 (0.0-0.0) 0.77 (0.38-
1.56)
NA
Open in a separate window
Abbreviations: HR, hazard ratio; NA, not applicable; NASH, nonalcoholic steatohepatitis; SHR, subhazard ratio.
Multivariable models were adjusted for sex, cirrhosis cause, decompensation, Charlson comorbidity index,
insurance, and year of cohort entry. For the mortality outcomes, HRs are reported; for other outcomes, SHRs are
reported. The HRs and SHRs refer to the relative changes per year.
Adjusted values could not be calculated because of the small number of outcomes.
Decompensation outcomes were assessed only in those with compensated cirrhosis at baseline.
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